Hyphens Pharma awarded e-pharmacy license for WellAway pharmacy

Download as PDF

Press Release 

  • WellAway Pharmacy will support medical clinics with e-pharmacy service and contribute to the Group’s Medical Hypermart and Digital business

Singapore, 8 January 2021 – Hyphens Pharma International Limited (凯帆药剂国际有限公司, Hyphens Pharma, or the Company, and together with its subsidiaries, the Group), Singapore’s leading specialty pharmaceutical and consumer healthcare group, is pleased to announce that its subsidiary, Pan-Malayan Pharmaceuticals Pte Ltd (“Pan-Malayan”), has been awarded with an e-pharmacy licence for its WellAway Pharmacy (“WellAway”) by the Health Sciences Authority (“HSA”).

WellAway aims to leverage on the medical and logistical expertise of Pan-Malayan, to work closely with medical clinics in Singapore, to provide a reliable and convenient medication delivery service to residential homes, complementing the increasing usage of telemedicine by our medical partners.

Mr Lim See Wah, Executive Chairman and Chief Executive Officer of Hyphens Pharma commented: “With the rise of telemedicine redefining healthcare systems all over the world, epharmacy and home delivery services have become increasingly important to ensure that patients receive essential medications on time. We hope WellAway will contribute to the evolving development of telemedicine in Singapore.”

The award will not have a material effect on the net tangible assets or earnings per share of the Group for the financial year ending 31 December 2021.



About Hyphens Pharma International Limited   

Hyphens Pharma International Limited and its subsidiaries (the “Group“) is Singapore’s leading specialty pharmaceutical and consumer healthcare group leveraging on its diverse footprint in ASEAN countries. The Group has a direct presence in Singapore, Vietnam, Malaysia, Indonesia and the Philippines, and is supplemented by a marketing and distribution network covering six additional jurisdictions, namely, Hong Kong, Myanmar, Brunei, Cambodia, Oman and Bangladesh. 

Singapore is the Group’s regional headquarters, where its strategic planning, finance, regulatory affairs, research and development, legal, business development and logistics operations are based. The Group’s core business comprises the following segments: Specialty Pharma Principals, Proprietary Brands, and Medical Hypermart and Digital. Besides marketing and selling a range of specialty pharmaceutical products in selected ASEAN countries through exclusive distributorship or licensing and supply agreements with brand principals mainly from Europe and the United States, the Group also develops, markets and sells its own proprietary range of dermatological products and health supplement products. In addition, the Group operates a medical hypermart for healthcare professionals, healthcare institutions and retail pharmacies, to supply pharmaceutical products and medical supplies.

For more information, please visit

Issued on behalf of the Company by Cogent Communications Pte. Ltd.

For enquiries, please contact:
Ms Candy Soh, Tel: (65) 6704 9284, Mob: (65) 9816 8391, Email: [email protected]
Mr Gerald Woon, Tel: (65) 6704 9268, Mob: (65) 9694 8364, Email: [email protected]

This press release has been prepared by the Company and its contents have been reviewed by the Sponsor for compliance with the Rules of Catalist. The Sponsor has not independently verified the contents of this press release.

This press release has not been examined or approved by the SGX-ST. The SGX-ST assumes no responsibility for the contents of this press release including the accuracy, completeness or correctness of any of the information, statements or opinions made or reports contained in this press release.

The contact person for the Sponsor is Mr Kelvin Wong, Senior Vice President, who can be contacted at 12 Marina Boulevard, Level 46, Marina Bay Financial Centre Tower 3, Singapore 018982, Telephone: +65 6878 8888.